Evidence map›Paper›PMID 34576123›Full record

ArticleInternational journal of molecular sciences2021

A Shotgun Proteomic Platform for a Global Mapping of Lymphoblastoid Cells to Gain Insight into Nasu-Hakola Disease.

Antonella De Palma, Anna Maria Agresta, Simona Viglio, Rossana Rossi, Maura D'Amato, Dario Di Silvestre, Pierluigi Mauri, Paolo Iadarola

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Microglia in Neurodegenerative Diseases.Advances in neurobiology · 2024
    Review
  4. Article
  5. Mass Spectrometric Proteomics 2022.International journal of molecular sciences · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Antonella De PalmaProteomics and Metabolomics Unit, Institute for Biomedical Technologies (ITB-CNR), 20054 Milan, Italy.ORCID 0000-0001-5937-8604
Anna Maria AgrestaProteomics and Metabolomics Unit, Institute for Biomedical Technologies (ITB-CNR), 20054 Milan, Italy.
Simona ViglioBiochemistry Unit, Department of Molecular Medicine, University of Pavia, 27100 Pavia, Italy.ORCID 0000-0001-5020-478X
Rossana RossiProteomics and Metabolomics Unit, Institute for Biomedical Technologies (ITB-CNR), 20054 Milan, Italy.ORCID 0000-0002-0313-7083
Maura D'AmatoBiochemistry Unit, Department of Molecular Medicine, University of Pavia, 27100 Pavia, Italy.ORCID 0000-0003-1294-3121
Dario Di SilvestreProteomics and Metabolomics Unit, Institute for Biomedical Technologies (ITB-CNR), 20054 Milan, Italy.ORCID 0000-0002-7143-6229
Pierluigi MauriProteomics and Metabolomics Unit, Institute for Biomedical Technologies (ITB-CNR), 20054 Milan, Italy.ORCID 0000-0003-4364-0393
Paolo IadarolaBiochemistry Unit, Department of Biology and Biotechnologies "L. Spallanzani", University of Pavia, 27100 Pavia, Italy.
University of Pavia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nasu-Hakola Disease (NHD) is a recessively inherited systemic leukodystrophy disorder characterized by a combination of frontotemporal presenile dementia and lytic bone lesions. NHD is known to be genetically related to a structural defect of TREM2 and DAP12, two genes that encode for different subunits of the membrane receptor signaling complex expressed by microglia and osteoclast cells. Because of its rarity, molecular or proteomic studies on this disorder are absent or scarce, only case reports based on neuropsychological and genetic tests being reported. In light of this, the aim of this paper is to provide evidence on the potential of a label-free proteomic platform based on the Multidimensional Protein Identification Technology (MudPIT), combined with in-house software and on-line bioinformatics tools, to characterize the protein expression trends and the most involved pathways in NHD. The application of this approach on the Lymphoblastoid cells from a family composed of individuals affected by NHD, healthy carriers and control subjects allowed for the identification of about 3000 distinct proteins within the three analyzed groups, among which proteins anomalous to each category were identified. Of note, several differentially expressed proteins were associated with neurodegenerative processes. Moreover, the protein networks highlighted some molecular pathways that may be involved in the onset or progression of this rare frontotemporal disorder. Therefore, this fully automated MudPIT platform which allowed, for the first time, the generation of the whole protein profile of Lymphoblastoid cells from Nasu-Hakola subjects, could be a valid approach for the investigation of similar neurodegenerative diseases.

Indexed as

ProteomicsCluster AnalysisDiscriminant AnalysisHumansLipodystrophyLymphocytesMembrane GlycoproteinsOsteochondrodysplasiasProtein Interaction MapsReceptors, ImmunologicSubacute Sclerosing PanencephalitisSystems BiologyMembrane GlycoproteinsReceptors, ImmunologicTREM2 protein, humanfrontotemporal dementiaLymphoblastoid cellsMudPITNasu-Hakola DiseaseproteomicsTREM2

Identifiers

PMID34576123
PMCPMC8472724
OpenAlexW3200467881

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.